The Experts below are selected from a list of 3348 Experts worldwide ranked by ideXlab platform
Pla Cancer - One of the best experts on this subject based on the ideXlab platform.
-
preliminary clinical study on hcpt combined with capecitabine and calcium folinate in treating patients with advanced colorectal carcinoma
Chinese clinical oncology, 2008Co-Authors: Hua Haiqin, Pla CancerAbstract:Objective:To observe the availability and the safety of the therapy of HCPT combine with capecitabine (xeloda) and calcium folinate tablets in colorectal cancer. Methods:A total of 44 patients with colorectal cancer were included in the study,which were received HLX chemotherapy regimen to the patients,that's 6mg per square meter of HCPT Parenteral Solution,added to 500ml of 0.9% sodium chloride injection,intervenous drop infusion days 1-14,and xeloda 1 250mg/m2 and calcium folinate tablets 50 mg p.o twice daily,oral application on days 1-14. To evaluate the near future therapeutic effect according to the RECIST standard and to evaluate the toxic reaction according to the NCI-CTC standard two weeks later. Results:Overall 242 cycles were administrated to the 44 patients (average 5-6 cycles per patients,range 2-8 cycles). Forty three patients could evaluate the near future therapeutic effect,44 patients could evaluate toxic reaction. The overall response rate (RR) was 25.6%,the disease control rate (DCR) was 62.8%. Two patients got clinic complted relief,9 patients got partial relief. The TTP was 6 months(95%CI,4.8-7.2 months),the common toxic reaction was bone marrow depression. Conclusion:The therapy of colorectal cancer with HLX chemotherapy regimen had indeed better therapeutic effect,moreover the toxic reaction was tolerant,further clinic application has more worthy.
Hua Haiqin - One of the best experts on this subject based on the ideXlab platform.
-
preliminary clinical study on hcpt combined with capecitabine and calcium folinate in treating patients with advanced colorectal carcinoma
Chinese clinical oncology, 2008Co-Authors: Hua Haiqin, Pla CancerAbstract:Objective:To observe the availability and the safety of the therapy of HCPT combine with capecitabine (xeloda) and calcium folinate tablets in colorectal cancer. Methods:A total of 44 patients with colorectal cancer were included in the study,which were received HLX chemotherapy regimen to the patients,that's 6mg per square meter of HCPT Parenteral Solution,added to 500ml of 0.9% sodium chloride injection,intervenous drop infusion days 1-14,and xeloda 1 250mg/m2 and calcium folinate tablets 50 mg p.o twice daily,oral application on days 1-14. To evaluate the near future therapeutic effect according to the RECIST standard and to evaluate the toxic reaction according to the NCI-CTC standard two weeks later. Results:Overall 242 cycles were administrated to the 44 patients (average 5-6 cycles per patients,range 2-8 cycles). Forty three patients could evaluate the near future therapeutic effect,44 patients could evaluate toxic reaction. The overall response rate (RR) was 25.6%,the disease control rate (DCR) was 62.8%. Two patients got clinic complted relief,9 patients got partial relief. The TTP was 6 months(95%CI,4.8-7.2 months),the common toxic reaction was bone marrow depression. Conclusion:The therapy of colorectal cancer with HLX chemotherapy regimen had indeed better therapeutic effect,moreover the toxic reaction was tolerant,further clinic application has more worthy.
Maria Luiza Moretti Branchini - One of the best experts on this subject based on the ideXlab platform.
-
Enterobacter cloacae sepsis outbreak in a newborn unit caused by contaminated total Parenteral nutrition Solution
American journal of infection control, 2000Co-Authors: Antonia Teresinha Tresoldi, Maria Clara Padoveze, Plínio Trabasso, Janice Franco Ferreira Da S. Veiga, Sérgio Tadeu Martins Marba, Angela Von Nowakonski, Maria Luiza Moretti BranchiniAbstract:Abstract Objective: The study aimed to investigate an outbreak caused by Enterobacter cloacae in a neonate intensive care unit. Design: A descriptive study of an outbreak of sepsis in high-risk neonates was used. Setting: The study was set in a tertiary care university teaching hospital. Patients: The patients were 11 neonates infected with Enterobacter cloacae whose symptoms and signs of sepsis developed during a 16-hour period. All but one neonate received Parenteral nutrition. Isolates from blood cultures, in-use Parenteral nutrition Solutions, and control aliquots of Parenteral nutrition Solution were typed by pulsed-field gel electrophoresis. Results: Enterobacter cloacae was found in the refrigerated aliquots of Parenteral nutrition Solution, in blood cultures from infected newborns, and from in-use Parenteral nutrition Solutions. All these strains of Enterobacter cloacae had the same antibiotic susceptibility pattern and the same genomic DNA profile. The strain isolated from the one patient who did not receive Parenteral nutrition presented a different susceptibility profile and genotype. Conclusion: The source of the nosocomial sepsis was the Parenteral nutrition Solution in 10 neonates. This contamination apparently occurred during preparation of the Parenteral Solution. (AJIC Am J Infect Control 2000;28:258-61)
Naseef Hani - One of the best experts on this subject based on the ideXlab platform.
-
Development and evaluation of Parenteral Solution containing florfenicol and flunixin meglumine for veterinary use
Global research online, 2018Co-Authors: Batrawi Nidal, Al-rimawi Fuad, Qurt, Moammal S., Naseef HaniAbstract:An article published in : International Journal of Pharmaceutical Sciences Review and Research, 52(2), September-October 2018 ; Article No. 07, Pages: 39-43Parenteral dosage forms are one of the most commonly used pharmaceutical dosage forms in veterinary medicine, at the same time the combination therapy of multiple drug products is a common practice in this field. The aim of this research was to develop a high quality, stable Solution that combines Florfenicol and Flunixin meglumine in a multidose injectable dosage form. Different organic solvents were tested to determine the optimal solvent for the active substances in the formulation. Citric acid was used in the formulation to overcome the problem of Flunixin instability and ethyl alcohol was incorporated in the formula in order to enhance syringeability and injectability of the Solution. All prepared formulations were evaluated for their chemical and physical stabilities. The candidate formula showed good physical and chemical stability after two weeks of storage at both room temperature and accelerated conditions. Samples from three pilot scale batches were stored at accelerated stability conditions for 6 months and didn’t show any significant physical or chemical instability. A generic Parenteral Solution drug product containing Florfenicol and Flunixin meglumine for veterinary use was successfully developed using mixture of organic solvents and excipientsAdvanced Veterinary Manufacturing Company (Palestine
-
Development and Evaluation of Parenteral Solution containing Florfenicol and Flunixin Meglumine for Veterinary Use
2018Co-Authors: Batrawi Nidal, Al-rimawi Fuad, Qurt Moammal, Naseef HaniAbstract:Parenteral dosage forms are one of the most commonly used pharmaceutical dosage forms in veterinary medicine, at the same time the combination therapy of multiple drug products is a common practice in this field. The aim of this research was to develop a high quality, stable Solution that combines Florfenicol and Flunixin meglumine in a multidose injectable dosage form. Different organic solvents were tested to determine the optimal solvent for the active substances in the formulation. Citric acid was used in the formulation to overcome the problem of Flunixin instability and ethyl alcohol was incorporated in the formula in order to enhance syringeability and injectability of the Solution. All prepared formulations were evaluated for their chemical and physical stabilities. The candidate formula showed good physical and chemical stability after two weeks of storage at both room temperature and accelerated conditions. Samples from three pilot scale batches were stored at accelerated stability conditions for 6 months and didn’t show any significant physical or chemical instability. A generic Parenteral Solution drug product containing Florfenicol and Flunixin meglumine for veterinary use was successfully developed using mixture of organic solvents and excipients.This research was supported by The Advanced Veterinary Manufacturing Company (Palestine)
Antonia Teresinha Tresoldi - One of the best experts on this subject based on the ideXlab platform.
-
Enterobacter cloacae sepsis outbreak in a newborn unit caused by contaminated total Parenteral nutrition Solution
American journal of infection control, 2000Co-Authors: Antonia Teresinha Tresoldi, Maria Clara Padoveze, Plínio Trabasso, Janice Franco Ferreira Da S. Veiga, Sérgio Tadeu Martins Marba, Angela Von Nowakonski, Maria Luiza Moretti BranchiniAbstract:Abstract Objective: The study aimed to investigate an outbreak caused by Enterobacter cloacae in a neonate intensive care unit. Design: A descriptive study of an outbreak of sepsis in high-risk neonates was used. Setting: The study was set in a tertiary care university teaching hospital. Patients: The patients were 11 neonates infected with Enterobacter cloacae whose symptoms and signs of sepsis developed during a 16-hour period. All but one neonate received Parenteral nutrition. Isolates from blood cultures, in-use Parenteral nutrition Solutions, and control aliquots of Parenteral nutrition Solution were typed by pulsed-field gel electrophoresis. Results: Enterobacter cloacae was found in the refrigerated aliquots of Parenteral nutrition Solution, in blood cultures from infected newborns, and from in-use Parenteral nutrition Solutions. All these strains of Enterobacter cloacae had the same antibiotic susceptibility pattern and the same genomic DNA profile. The strain isolated from the one patient who did not receive Parenteral nutrition presented a different susceptibility profile and genotype. Conclusion: The source of the nosocomial sepsis was the Parenteral nutrition Solution in 10 neonates. This contamination apparently occurred during preparation of the Parenteral Solution. (AJIC Am J Infect Control 2000;28:258-61)
